← Back to catalogue

FilmArray® NGDS Warrior Panel

FDA UDI

by BioFire Defense, LLC

Identity

Trade Name
FilmArray® NGDS Warrior Panel FDA UDI
Generic Name
Multiple-type biothreat/febrile infection-associated pathogen nucleic acid IVD, kit, nucleic acid technique (NAT) FDA UDI
Device Name
FilmArray® NGDS Warrior Panel - IVD reagent Biothreat Detection Kit containing 30 tests. FDA UDI
Model / Reference
NGDS-ASY-0007 FDA UDI
Description
FilmArray® NGDS Warrior Panel - IVD reagent Biothreat Detection Kit containing 30 tests. FDA UDI

Identifiers

Catalog Number
NGDS-ASY-0007 FDA UDI
Primary DI / UDI-DI
00851458005136 FDA UDI
510(k) Number
K170883 FDA UDI
FDA Product Code
PRD FDA UDI
NSU FDA UDI
GMDN Term
Multiple-type biothreat/febrile infection-associated pathogen nucleic acid IVD, kit, nucleic acid technique (NAT) FDA UDI

Classification

Regulation Number
862.2570 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

Yes

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

Yes

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

Yes

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Multiple-type biothreat/febrile infection-associated pathogen nucleic acid IVD, kit, nucleic acid technique (NAT)

FilmArray® NGDS Warrior Panel by BioFire Defense, LLC — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Multiple-type biothreat/febrile infection-associated pathogen nucleic acid IVD, kit, nucleic acid technique (NAT).

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Sources (1)

  • FDA UDI 5d14f47c-2637-4cad-9153-2287e6921a57 36 fields · synced May 31, 2026